GlobeNewswire Inc | Apr 16, 2021 08:05AM EDT

April 16, 2021

-- Adverum to host webcast with key opinion leaders onSunday, May 2, 2021 at 7:00 AM PT--

REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, todayannounced the presentation of additional clinical data for Cohorts 1-4in the OPTIC clinicaltrial of ADVM-022 intravitreal (IVT) injection gene therapy in wet age-related macular degeneration (wet AMD) during the Association for Research in Vision and Ophthalmology (ARVO) 2021VirtualMeeting. Preclinical data on ADVM-062, a novel IVT gene therapy that also utilizes Adverums proprietary vector capsid AAV.7m8, in blue cone monochromacy will also be presented.

Presentation Title: Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)Session: AMD: Clinical research - New Therapies and TechnologiesDate and Time: May 3, 2021 from 4:30 PM to 6:00 PM ETPresenter: Brandon G. Busbee, M.D., partner, Tennessee Retina Physicians

Poster Title: Preclinical Evaluation of ADVM-062, a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone MonochromacySession: Drug Delivery and Gene TherapyDate and Time: May 3, 2021 from 11:15 AM to 1:00 PM ETPresenter:RuslanGrishanin,director translational science,AdverumBiotechnologies

On Saturday, May 1, 2021 at 7:00 AM ET,the virtual presentations will be available on demand toARVOparticipants.Adverumplans to post theADVM-022 OPTICpresentation underEvents and Presentationsin the Investors section of Adverums website.The ADVM-062 BCMposterwill be availablein thePublicationssection of Adverums website.

AdverumWebcastDate:May2, 2021Time: 7:00 8:30 AM PT (10:00 11:30 AM ET)Key Opinion Leaders Participating:

-- Brandon G. Busbee, M.D., partner, Tennessee Retina Physicians; Investigator in OPTIC -- Jeffrey S. Heier, M.D., director of the Vitreoretinal Service and director of Retina Research at Ophthalmic Consultants of Boston

The live video webcast will be accessible underEvents and Presentationsin the Investors section of Adverum's website. To participate in the conference call, dial 1-877-705-6003(domestic) or 1-201-493-6725(international) and refer to the AdverumBiotechnologies OPTIC Clinical Data Discussion Conference Call. It is recommended call participants dial in 15 minutes in advance. The archived audio webcast will be available on Adverumswebsite following the call and will be available for 30 days.

OnMay 6, 2021after market,Adverumplans to report recent business progress and financial results for thefirstquarter of 2021.

About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

Investor Relations ContactsMyesha LacyAdverum Biotechnologies, Inc.T: 650-649-1257E: mlacy@adverum.com

Amy FigueroaAdverum Biotechnologies, Inc.T: 650-823-2704E: afigueroa@adverum.com

Media ContactAndrea CohenSam Brown Inc.T: 917-209-7163E: andreacohen@sambrown.com